Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program
Clinical Cancer Research (2015) - Comment
pubmed: 25500058  doi: 10.1158/1078-0432.ccr-14-2572  issn: 1078-0432  issn: 1557-3265 

Malcolm A. Smith, C. Patrick Reynolds, Min H. Kang, E. Anders Kolb, Richard Gorlick, Hernan Carol, Richard B. Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Dmitry Lyalin, Raushan T. Kurmasheva, Peter J. Houghton